Call to Schedule Free Consultation at Over 45 Centers Worldwide!
Call to Schedule Free Consultation at Over 45 Centers Worldwide!
Research-Based Insight on Stem Cells and Lyme Recovery
Free Download: Stem Cell Therapy for Autism
Disclaimer:
The information provided by R3 Stem Cell is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and are not guaranteed. The FDA considers stem cell therapy experimental at this point.
Any claims made on this website refer to procedures performed OUTSIDE of the USA. R3 Stem Cell has clinics in Mexico, Philippines, South Africa, Turkey, India, Pakistan.
Every day, R3 Stem Cell receives inquiries worldwide from individuals asking if stem cell therapy can help with Lyme Disease. Spoiler alert: It can help a lot! In this guide, we’ll go through the basics of how stem cells and exosomes work, the latest research, and what to expect with a regenerative procedure.
Lyme disease is a bacterial infection you get from the bite of an infected tick. At first, Lyme disease usually causes symptoms such as a rash, fever, headache, and fatigue. But if it is not treated early, the infection can spread to your joints, heart, and nervous system.
The first recognition of Lyme disease, also called borreliosis, began in 1975 when many children received a diagnosis of juvenile rheumatoid arthritis in Lyme, Connecticut, and two neighboring towns. Researchers found that bites from infected deer ticks were responsible for the outbreak of arthritis.
The species of Ixodes ticks that transmit the disease are commonly found throughout temperate regions of North America, Europe, and Asia. Currently, the Centers for Disease Control and Prevention (CDC) estimate approximately 300,000 new cases of Lyme disease in the United States alone each year. However, due to climate change, shifting land use patterns, and the relative abundance and distribution of reservoir hosts, it is anticipated that the geographic range of the tick vector will continue to expand. For instance, the number of reported cases in Canada has increased six-fold over the past decade, with particular increases in the eastern provinces of Nova Scotia and Ontario.
It is considered as a multi-organ-system infectious disease as its typical symptoms include fever, muscle and joint pain, swollen lymph nodes, headache, fatigue, and erythema migrans (rash with a bull’s eye appearance). If left untreated, it affects joints, heart, eyes, etc. However, the nervous system, i.e., the central nervous system (CNS), the peripheral nervous system (PNS), and the autonomic nervous system (ANS), appear to be its primary targets.
We’re available to discuss Lyme and regenerative therapy—call (844) GET-STEM.
Antibiotics, usually doxycycline or amoxicillin, are effective treatments for Lyme disease. How long your treatment lasts depends on the stage of infection. In general, it’s true that the sooner you’re treated, the quicker and more complete your recovery.
Up to 20% of those with Lyme Disease experience long-term symptoms, which can seriously affect quality of life. This may be due to initially undiagnosed Lyme, or Lyme that failed treatment.
“Post-treatment Lyme disease syndrome (PTLDS) is a real disorder that causes severe symptoms in the absence of clinically detectable infection,” says John N. Aucott, M.D., associate professor of medicine at the Johns Hopkins University School of Medicine and director of the Johns Hopkins Lyme Disease Clinical Research Center.
The cause of post-treatment Lyme disease syndrome is unknown and is a huge source of debate in the medical community. But there are a few theories.
One theory is that there are leftover reservoirs of the bacteria that cause Lyme disease after antibiotic treatment. Others argue that people who develop PTLDS have an underlying autoimmune condition, as Lyme disease can alter and weaken the immune system. Lyme disease is also often misdiagnosed as an autoimmune disorder such as Rheumatoid Arthritis.
Some other possible theories include:
Researchers have been able to find a correlation between more severe symptoms at presentation, more widely spread symptoms, and delayed antibiotic treatment with the development of PTLDS in those same patients.
About 50 percent of the PTLDS patients reported severe fatigue, about 28 percent reported severe pain, about 23 percent reported severe cognitive complaints and about 31 percent reported severe sleep difficulty.
Signs and symptoms of untreated Lyme disease (or those with failed treatment), which may happen from months to a year after infection, may include:
Antibiotic-refractory late Lyme arthritis, the most studied post-treatment manifestation of Lyme disease, is thought to be autoimmune in nature, as B. burgdorferi (the tick bacteria) can no longer be found in the joint or surrounding tissue in patients who have been thoroughly treated.
Connect with R3 about stem cell options for chronic Lyme— (844) GET-STEM.
Research into stem cell therapy for chronic Lyme Disease is limited, but what does exist has been very positive.
In the first case report published on stem cell therapy for Lyme disease, an 18-year-old white male with a past medical history significant for Lyme disease and other infections presented with chief complaints of moderate fatigue, sore throats that would come and go, frequent sinusitis, diarrhea once a month, back stiffness and neck pain, mild tremors of the hands, insomnia, and moderate cognitive difficulties.
He was diagnosed with Lyme Disease at the age of 10 after a tick bite one year prior. The initial test was negative, but it turned positive for Lyme on subsequent testing. Since the patient continued to suffer from recurrent infections with frequent relapses on IVIG, at age 18, the patient and his mother decided to undergo human embryonic stem cell treatment. The source of cells was not described, and the number of cells wasn’t reported either.
Of note, R3 Stem Cell does NOT use embryonic stem cells. Rather, R3 uses mesenchymal or hematopoietic stem cells. They work well and are very safe.
The 1st set of treatments were performed in 2016 for 8 weeks in New Delhi, India; the 2nd set of treatments were for 4 weeks six months later, and the last set of treatments were over two weeks, six months after that. These were given through multiple routes, primarily IM and IV, although several were given through the cervical intrathecal route.
After the stem cell therapy, the patient has clinically stabilized with fewer sinus infections and his IgG immunoglobulin levels and subclasses have remained within normal limits. The patient’s Lyme disease symptoms also improved. He no longer complained of significant fatigue or insomnia and only required low-dose Adderall for his ADHD (5 mg/day) to help him concentrate at school.
There remained only mild neck and back pain, but it was positional, with no other associated joint pain or neuropathy. Recent testing for Lyme disease showed decreased Borrelia-specific bands on the Western blot (31 kDA, i.e., Osp A, as well as a decrease in the 39 kDA band) with negative whole blood PCRs.
He remained clinically stable without relapses while off all antibiotics and only required a seven-day course of a cephalosporin for a sinus infection during his first year of college. Previously, he had suffered from an average of 10–15 infections per year, despite being on monthly IVIG. By the end of follow up, he was at a high level of normal functioning.
A 2018 study out of India included 59 patients with Lyme disease whose single-photon emission tomography imaging was performed before and after human embryonic stem cell therapy. The Single-photon emission tomography imaging was used to assess the hypoperfused lesions/regions in the brain prior to the therapy, as well as the improvement in perfusion after human embryonic stem cell treatment.
The author noted that patients with LD usually suffer from poor circulation in brain regions affecting memory and cognition, with an overflow in the occipital lobe. This might be the cause of poor concentration, cognitive disabilities and highly sensitive eyes in LD patients.
Of note, R3 Stem Cell does NOT use embryonic stem cells. R3 uses mesenchymal and hematopoietic stem cells obtained from ethical sources. The SPECT imaging was performed for all the patients, before and after the treatment. A clear and noticeable improvement was observed and reported after comparing the reports of SPECT imaging before and after the therapy. Patients with significant improvement showed more than 60% improvement. The clinical improvement was based on the brain perfusion state of patients. After comparing the SPECT imaging results of prior and after therapy, it was observed that the patients showed an improvement. They were observed with severe/moderate/mild brain hypoperfusions prior to therapy. After receiving stem cell therapy, their perfusion level upgraded to moderate/mild/minimal and even normal perfusion levels.
Another study performed by Shroff in 2016 evaluated a patient with diagnoses of Lyme Disease and Multiple Sclerosis (MS). Globally, MS prevalence parallels the circulation of the Lyme disease (LD), which is characterized by white matter lesions in the brain similar to those found in MS patients.
In the study, a 30-year-old female presented with chief complaints of inability to walk, wheel chair dependence, unable to stand without support, spasticity of lower limbs with foot drop on the left foot, weakness of the left arm and spasticity of the left hand, severe fatigue with myalgia, and joint pains especially in the shoulder (left >right). After further deterioration of her condition, she was tested and found positive for LD in 2012. She was prescribed an antibiotic regime without much beneficial results.
The patient received stem cell therapy along with antibiotics and physiotherapy. The treatment period for the patient included six months and was poorly described in the paper. Following the first treatment phase, the patient reported remarkable improvement in her lower limb strength, decreased spasticity, and had no longer fatigue issues. Also, she was able to walk upright now with support.
After her second visit, improvement in muscle strength, movement of left upper arm, spasticity of left lower, and left upper limb was observed. The patient was able to walk independently for up to 40–50 minutes around the room. An improvement was observed in parameters like muscle weakness, walking distance, balance, fatigue, pain, blurring of eyes, and deformity.
Speak with our expert doctors about Lyme-related treatment plans: (844) GET-STEM.
R3 is used to perform autologous therapies, where a patient’s own bone marrow or adipose stem cells are used. However, a lot of stem cells in one’s body are as old as that person is, and hence not very active. Their ability to successfully increase sufficient blood flow and allow for tissue regeneration is inferior to umbilical cord stem cells, which are young, potent and extremely active.
Specifically, the therapeutic potential of autologous bone marrow or adipose stem cells in the treatment of older patients is impaired by a number of age-related factors such as oxidative stress, telomere length, DNA damage, disease, and long-term use of some medications.
This is in stark contrast to the youthful genotype and phenotype of neonatal tissue-derived stem cells, such as from the umbilical cord. They are better at facilitating repair and regeneration of tissue damage, creating new blood flow with superior anti-inflammatory and immunomodulatory efficacy compared to mature stem cells from one’s adipose or bone marrow.
As a result of the inferiority of autologous stem cells due to the reasons above and better results being seen with umbilical cord stem cells, R3 only uses the donor stem cells today.
Stem cells and exosomes act in the body through several mechanisms. They do NOT become part of a patient’s DNA, which means they do not engraft into the person’s existing cells. The predominant method of action is thought to be through paracrine mechanisms, which means “cell to cell” interaction.
They act through:
Along with offering MSCs for treatment of Lyme Diseases, R3 Stem Cell includes stem cell exosomes, which are a type of extracellular vesicle participating in extensive cell to cell communication for new blood flow creation.
Find out if you’re a candidate for stem cell therapy— (844) GET-STEM.
R3 Stem Cell’s regenerative biologics originate from umbilical cord tissue that has been donated after a scheduled c-section. No baby (or mother) is harmed during the c-section procedure. The umbilical cord tissue is normally discarded, but if the mother passes screening test then the umbilical cord is immediately sent to the lab.
The lab carefully processes the umbilical cord to generate large amounts of stem cells and exosomes that are of the highest quality possible. The lab team consists of multiple PhD’s working in ISO Certified, cGMP compliant clean rooms to ensure quality assurance that exceeds USA FDA standards. The proprietary production process combines the highest potency, safety and affordability for providers to confidently offer exosome procedures.
Millions of dollars have been invested into the pharmaceutical grade production of the biologics including first rate clean rooms, bioreactors, nano-particle tracking analyzers, cytometers, PCR, tangential flow machines and real time environmental monitoring. The quality assurance testing complies with screening and testing stan¬dards consistent with the American Association of Tissue Banks, cGMP standards, FDA regulations and the highest level of any regulatory agency globally.
R3 Stem Cell’s Centers of Excellence globally include umbilical cord stem cell derived exosomes with umbilical cord stem cells to provide enhanced results. Exosomes are lipid bound vesicles (acellular) produced by cells that contain a plethora of growth factors, cytokines, mRNA and other proteins.
They are exceptionally helpful in cell to cell communication, and very effective for reducing inflammation when they become ingested by their recipient cell. They act as shuttles to send nucleic acids and proteins to other cells, in this way, allowing cell-tocell communication and transporting molecules among both close and distant cells. In general, these released proteins are important regulators of intracellular information.
Exosomes could be the mediators of many stem cell-associated therapeutic activities. Considering they are 100 times smaller than stem cells, they do not have any issues passing through the blood-brain-barrier to reach the brain from the bloodstream.
Exosomes can be derived from many different types of stem cells including umbilical cord, cardiosphere-derived cells, cardiac stem cells, embryonic, induced pluripotent, mesenchymal and endothelial progenitor cells. They can carry and deliver mRNAs, miRNAs and proteins to the injured heart muscle and play a significant role in resident cardiac stem cell activity, cardiomyocyte proliferation, beneficial cardiac remodeling, apoptosis reduction, angiogenesis, antiinflammatory response and a decrease in infarct size. The advantages for effective exosome therapy include the cell-free component, long-term stability and low or no immune response.
Book your no-obligation call at (844) GET-STEM.
Is stem cell therapy safe?
After a decade of performing over 24,000 stem cell procedures worldwide, R3 knows that the regenerative procedures are safe. The quality control employed during the stem cell production is second to none, and the side effects R3 sees are usually mild to moderate and temporary.
They may include itching, dizziness, lightheadedness, low grade fever, chills, headache, nausea. These are typically temporary. If a patient has an allergic reaction to the multivitamin or a preservative, all of R3’s Centers have the medications to resolve it quickly.
One of the questions we get asked a lot is, “Will the stem cells get rejected?” The answer is NO.
MSCs do not express major histocompatibility complex (MHC) antigens of the class II subtype and contain low levels of MHC molecules of the class I subtype. MSCs also lack the co-stimulatory molecules essential for immune detection, including CD40, CD80, and CD86.
Therefore, MSCs generally have low immunogenicity and can avoid immune rejection by the recipient, which serves as the foundation for their successful application without needing to match the donor to the recipient. Scientists call this being “immunologically privileged”.
Another question often asked is “Is there a chance of a tumor forming?” Once again the answer is NO. The mesenchymal stem cells and exosomes used during treatment have never been shown to have tumor forming potential. In fact, they have been shown to be anti-tumor forming.
Treatment Protocol
For the past decade, R3 has been successfully treating patients with stem cell and exosome therapies with injection, infusion, intranasal, intrathecal and nebulizer procedures.
For heart disease, R3’s providers use between one and two million stem cells per kilogram (depends on patient weight). In addition, billions of stem cell exosomes and platelet rich plasma therapy (PRP) are included at no cost.
R3 Stem Cell’s heart disease treatment protocol includes an IV therapy combining mesenchymal stem cells and exosomes, along with a multivitamin IV as well. Safety is paramount with the biologics products being rigorously tested prior to use, and expert providers managing each treatment as if you were a family member! This is why we don’t perform the heart catheterization application, as patients in some studies have suffered significant adverse events as a result.
Why does R3 Stem Cell use donor tissue for its stem cells?
Although autologous (your own) stem cells provide significant advantages, allogeneic (donor) stem cells have more advantages. First of all, autologous MSCs need a long time to culture and expand, which limits its application in treatment, while allogeneic stem cells can be obtained and expanded more quickly, thus avoiding the delay of time window.
Second, age is a factor that affects the physiological characteristics of MSCs. Studies have shown that stem cells from elderly donors have decreased proliferation and differentiation ability. This means they are less in number and less effective!
Affordability
Stem cell therapy for psoriasis may be the key step to completely changing a person’s quality of life, and we want to make it affordable for as many individuals as possible. Our global volume has allowed us to keep our patient costs as low as possible.
Unfortunately, stem cell clinics in Colombia, China and Panama charge over $20,000 USD for psoriasis treatment. How are individuals supposed to budget for that?? R3 Stem Cell’s fees are typically less than half that for full treatment, which also includes free exosomes, PRP and a multivitamin infusion!
R3’s Experience
For the past decade, R3 Stem Cell’s Centers globally have performed over 24,000 regenerative procedures in six countries. Patient satisfaction across all conditions treated is very high, at 85%. R3 has treated many patients with varying types of heart disease.
R3 combines safety, effectiveness and affordability for the therapies. Internationally, the Intellicell is used, which is culturing the most active mesenchymal stem cells to create the “smartest” stem cell in the world!
R3 Stem Cell offers free consultations for individuals to discuss whether regenerative therapy is indicated for their Lyme Disease. Simply call (844) GET-STEM or +1 (480) 808-7057 to schedule yours!
Disclaimer: This guide’s education does not constitute medical advice. The USA FDA considers stem cell therapy experimental. Any claims made in this Guide refer to procedures performed outside of the USA.
References
David Greene, MD, PhD, MBA, Founder/CEO
R3 Stem Cell offers treatments that bring patients hope and options. Hope that surgery can be avoided, and tissue injury can be repaired with patients being able to get back to desired activities.
Founder and CEO David Greene, MD, PhD, MBA writes extensively on regenerative medicine and gives many seminars worldwide on a regular basis. With over forty Centers of Excellence globally, R3 is at the forefront of regenerative therapies.
R3’s Centers have successfully performed over 25,000 regenerative procedures to date. Call today for your free consultation (844) GET-STEM!
No portion of this Document may be reproduced without the Express Written Consent of R3 Stem Cell.
Disclaimer: This guide’s education does not constitute medical advice. The USA FDA considers stem cell therapy experimental. Any claims made in the Guide refer to procedures performed outside the USA.
Brand Ambassador Gallery
The USA stem cell leader offers procedures in
7 Countries including:
SUCCESS STORIES
R3 STEM CELL MASTER CLASS
Learn everything you need to know about the ever expanding field of regenerative medicine in this 8 part series that includes over four hours of entertaining content!
R3 STEM CELL INTERNATIONAL
R3 Stem Cell International includes 45 clinics in 7 countries. These Centers of Excellence treat all types of conditions with safe, effective protocols by expert stem cell physicians.
FREE STEM CELL CONSULTATION
R3 Stem Cell offers a no cost consultation to see if you or a loved one is a candidate for regenerative cell therapies including cytokines, growth factors, exosomes, and stem cells.
PROVIDER PARTNERSHIP
The R3 Partnership Program offers providers an all-in-one regenerative practice program including marketing, consultations and booked procedures!
The information provided by R3 Stem Cell is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and only your medical professional can explain all the risks and potential benefits of any therapy based on your circumstances. R3 Stem Cell does not recommend or endorse any specific tests, products, procedures, opinions, or other information that may be mentioned on this website. Reliance on any information provided by R3 Stem Cell, its employees, others appearing on this website at the invitation of R3 Stem Cell, or other visitors to the website is solely at your own risk. R3 Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.
CALIFORNIA
FLORIDA
GEORGIA
HAWAII
IDAHO
ILLINOIS
INDIANA
IOWA
KANSAS
KENTUCKY
LOUISIANA
MARYLAND
MASSACHUSETTS
MICHIGAN
MINNESOTA
MISSISSIPPI
MISSOURI
NEBRASKA
NEW JERSEY
NEW YORK
NEW MEXICO
NEVADA
NORTH CAROLINA
OHIO
OKLAHOMA
OREGON
PENNSYLVANIA
RHODE ISLAND
SOUTH CAROLINA
SOUTH DAKOTA
TENNESSEE
Disclaimer: The city links above provide general information on stem cell treatment. To find an R3 Stem Cell clinic near you click here
The USA stem cell leader offers procedures in
7 Countries including:
Copyright © 2017-2025 R3 Stem Cell. All Rights Reserved.
